Skip to main content
. 2022 Oct 26;14(21):5243. doi: 10.3390/cancers14215243

Table A2.

Univariable and multivariable logistic regression without item on dissatisfaction with scar.

Population Characteristics Univariable Logistic Regression 1 Multivariable Logistic Regression 2
X2 = 1167.91 (p-Value < 0.001) Nagelkerke R2 = 0.47
OR [95%CI] p-Value OR [95%CI] p-Value
Age at questionnaire 1.00 [0.99–1.01] 0.633
Gender Male Reference Reference
Female 3.66 [2.89–4.62] <0.001 4.07 [2.66–6.23] <0.001
Partner Yes Reference Reference
No 2.06 [1.66–2.55] <0.001 1.18 [0.88–1.59] 0.272
Level of education Low 2.26 [0.89–5.75] 0.086 1.79 [0.39–8.19] 0.452
Medium 1.39 [1.16–1.66] <0.001 0.98 [0.77–1.25] 0.869
High Reference Reference
Type of cancer Melanoma Reference Reference
Head and neck 1.13 [0.51–2.51] 0.757 0.99 [0.37–2.65] 0.977
Digestive tract other 3 2.98 [1.09–8.12] 0.033 3.07 [0.76–12.39] 0.115
Colon and rectal 1.21 [0.41–2.97] 0.682 0.61 [0.19–1.97] 0.409
Breast 3.28 [2.02–5.31] <0.001 1.88 [0.91–3.90] 0.091
Female genitalia 3.57 [2.14–5.96] <0.001 2.64 [1.36–5.14] 0.004
Thyroid gland 1.67 [0.91–3.05] 0.098 0.66 [0.30–1.48] 0.311
Central nervous system 2.07 [1.08–3.96] 0.029 0.76 [0.24–2.34] 0.627
Bone and soft tissue sarcoma 1.55 [0.80–3.00] 0.195 1.28 [0.54–3.02] 0.577
Germ cell tumor 0.72 [0.41–1.26] 0.243 2.05 [0.92–4.60] 0.080
Lymphoid hematological malignancies 2.06 [1.24–3.45] 0.006 1.92 [0.91– 4.03] 0.087
Myeloid hematological malignancies 2.34 [1.24–4.43] 0.009 2.03 [0.68–6.06] 0.207
Other 4 1.68 [0.75–3.75] 0.208 0.80 [0.28–2.30] 0.682
Tumor stage I Reference Reference
II 1.63 [1.30–2.02] <0.001 1.57 [1.12–2.21] 0.009
III 1.29 [0.97–1.08] 0.076 1.52 [0.99–2.34] 0.059
IV 1.48 [0.96–2.26] 0.074 1.83 [0.98–3.43] 0.059
Missing 1.18 [0.86–1.60] 0.304 1.19 [0.58–2.44] 0.631
Chemotherapy 5 No Reference Reference
Yes 1.42 [1.18–1.72] <0.001 0.68 [0.47–0.98] 0.040
Radiotherapy 5,6 No Reference Reference
Yes 1.48 [1.23–1.77] <0.001 1.22 [0.92–1.61] 0.162
Hormone therapy 5 No Reference Reference
Yes 2.16 [1.71–2.74] <0.001 1.26 [0.83–1.90] 0.277
Targeted therapy 5 No Reference Reference
Yes 1.34 [0.98–1.83] 0.067 0.92 [0.59–1.42] 0.695
Surgery organ 5 No Reference
Yes 1.03 [0.85–1.25] 0.771
Surgery local 5 No Reference
Yes 0.87 [0.67–1.14] 0.308
Stem cell transplantation 5 No Reference
Yes 1.39 [0.81–2.40] 0.237
Time since diagnosis <10 years 1.45 [1.16–1.82] 0.001 1.28 [0.95–1.73] 0.110
10–15 years 1.08 [0.85–1.37] 0.520 1.00 [0.73–1.35] 0.983
>15 years Reference Reference
Physical activity MET hours/week 1.00 [1.00–1.00] 0.063 1.00 [1.00–1.00] 0.099
BMI Underweight 1.83 [0.94–3.58] 0.078 0.71 [0.28–1.75] 0.453
Normal weight Reference Reference
Overweight 1.27 [1.03–1.57] 0.028 1.79 [1.36–2.37] <0.001
Obesity 3.59 [2.81–4.59] <0.001 3.82 [2.74–5.33] <0.001
Maladaptive coping style 1.19 [1.17–1.22] <0.001 1.09 [1.06–1.13] <0.001
HRQoL Physical functioning 0.95 [0.95–0.96] <0.001 0.99 [0.98–1.00] 0.146
Role functioning 0.97 [0.96–0.97] <0.001 0.99 [0.99–1.00] 0.045
Emotional functioning 0.95 [0.94–0.95] <0.001 0.97 [0.96–0.98] <0.001
Cognitive functioning 0.97 [0.96–0.97] <0.001 0.99 [0.99–1.00] 0.001
Social functioning 0.96 [0.96–0.96] <0.001 0.99 [0.98–0.99] <0.001
Global Health status 0.94 [0.94–0.95] <0.001 0.98 [0.97–0.99] <0.001
Sexual attractiveness No Reference Reference
Yes 5.16 [3.75–7.11] <0.001 3.39 [2.29–5.01] <0.001

1 Univariable: p-value < 0.1 is included in multivariable analyses. 2 Multivariable: p-value < 0.05 is significant (bold p-values show a statistically significant OR). The multivariable model showed no multicollinearity. 3 Digestive tract and other includes the esophagus, stomach, and small intestine. 4 Other includes respiratory, male genitalia (penis, prostate), urinary tract, tumor with other localizations, endocrine glands, eye, neuroblastoma, paraganglioma. 5 The treatments were received at primary diagnosis. 6 Radiotherapy includes radiotherapy for primary tumor and metastases at primary diagnosis. OR [95%CI] = odds ratio and 95% confidence interval.